Cell Cycle Progression Score Identifies Biopsy‐Undetected Grade Group 5 Prostate Cancer
The Prostate · 2025
DOI: 10.1002/pros.70112 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Prostate, 2025. Verfasst von Yu Ozawa und 6 weiteren Autor:innen. Beteiligte Einrichtung: AdventHealth Global Robotics Institute, Celebration, Florida, USA. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Cell Cycle, Prostate. Die Arbeit nennt 32 Literaturangaben.
Abstract (Originalsprache)
Background
Grade Group 5 (GG5) prostate cancer carries the poorest prognosis, yet it is often undetected at biopsy. We evaluate whether Cell Cycle Progression (CCP) score identifies biopsy‐undetected GG5 disease and improves risk stratification when combined with Cancer of the Prostate Risk Assessment (CAPRA) score.
Methods
A total of 430 patients with biopsy‐confirmed GG1–4 underwent Prolaris® testing before immediate radical prostatectomy (RP). Logistic regression assessed the association between CCP score and pathological GG5 at RP. Predictive models using CCP, CAPRA, and clinical cell‐cycle risk (CCR) score were compared using area under the curve (AUC), decision curve analysis (DCA), and net reclassification improvement (NRI).
Results
Although GG5 was not frequent (7.2%), CCP score independently predicted GG5 ( p < 0.001) before and after adjusting for CAPRA and biopsy core number obtained. AUCs were 0.71 (95% CI: 0.60–0.83) for CCP, 0.67 (0.56–0.77) for CAPRA, 0.77 (0.67–0.87) for CCP + CAPRA, and 0.74 (0.64–0.84) for CCR. Both CCP + CAPRA and CCR outperformed CAPRA (DeLong's test, p = 0.008 and 0.001, respectively). DCA showed greater net benefit for CCP + CAPRA at thresholds 0.05–0.50 and for CCR at 0.05–0.40. CCR score yielded a higher overall NRI of 0.90 (95% CI: 0.55–1.20), improving classification for both events and non‐events. A significant positive CCP–CAPRA interaction was identified: GG5 was observed in 5.7% (24/421) of patients with CCP ≤ 4.6 and/or CAPRA ≤ 4, versus 78% (7/9) with both > 4.6 and ≥ 5 ( p = 0.039).
Conclusions
Our data suggests that CCP score adds value to initial risk assessment, particularly in CAPRA‐defined low‐ to favorable‐intermediate‐risk patients. An elevated CCP score should prompt counseling on the increased risk of biopsy‐undetected GG5 disease and consideration of intensified management, such as RP or radiotherapy with prolonged androgen deprivation therapy within a multimodal framework. This is especially relevant in non‐surgical settings where final pathology is unavailable. Clinical Trial Registration: N/A.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- AdventHealth Global Robotics Institute, Celebration, Florida, USA.
- Urology Department, University of Central Florida (UCF), Orlando, Florida, USA.
- Big and Open Data Innovation Laboratory (BODaI-Lab), University of Brescia, Brescia, Italy.
ORCID-Profile: Yu Ozawa, Marco Sandri, Shady Saikali
Zitieren
APA
Ozawa, Y., Moschovas, M. C., Sandri, M., Sharma, R., Saikali, S., Rogers, T., & Patel, V. (2025). Cell Cycle Progression Score Identifies Biopsy‐Undetected Grade Group 5 Prostate Cancer. The Prostate. https://doi.org/10.1002/pros.70112
Vancouver
Ozawa Y, Moschovas MC, Sandri M, Sharma R, Saikali S, Rogers T, et al. Cell Cycle Progression Score Identifies Biopsy‐Undetected Grade Group 5 Prostate Cancer. The Prostate. 2025. doi:10.1002/pros.70112
BibTeX
@article{Ozawa2025,
author = {Ozawa, Yu and Moschovas, Marcio Covas and Sandri, Marco and Sharma, Rohan and Saikali, Shady and Rogers, Travis and Patel, Vipul},
title = {Cell Cycle Progression Score Identifies Biopsy‐Undetected Grade Group 5 Prostate Cancer},
journal = {The Prostate},
year = {2025},
doi = {10.1002/pros.70112}
}
EUVIMED